ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2009
PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors.
Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 1 synthesis or guideline pooled it, 131 citations in OpenAlex.
- Pooled it
- PSD-95 drives binocular vision maturation critical for predation.bioRxiv : the preprint server for biology · 2026Article
- A suite of engineered mice for interrogating psychedelic drug actions.Nature neuroscience · 2026Article
- The working lives of neuronal 5-HTRSC chemical biology · 2026Review
- No evidence for direct physical interaction of 5-HTbioRxiv : the preprint server for biology · 2026Article
- Mechanistic insights toward dissociating therapeutic from psychedelic effects: bridging the gap between psychedelic research and mental health care.Translational psychiatry · 2026Review
- Serotonergic modulation of excitatory synapse development and plasticity.Molecules and cells · 2026Review
- The polypharmacology of psychedelics reveals multiple targets for potential therapeutics.Neuron · 2025Article
- Psilocybin as Transformative Fast-Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms.Fundamental & clinical pharmacology · 2025Review
- Decoupling of cortical activity from behavioral state following administration of the classic psychedelic DOI.Neuropharmacology · 2024Article
- Making Sense of Psychedelics in the CNS.The international journal of neuropsychopharmacology · 2024Article
- Psychedelics: preclinical insights provide directions for future research.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Review
- An Overview on the Hallucinogenic Peyote and Its Alkaloid Mescaline: The Importance of Context, Ceremony and Culture.Molecules (Basel, Switzerland) · 2023Review
- A suite of engineered mice for interrogating psychedelic drug actions.bioRxiv : the preprint server for biology · 2023Article
- G protein-coupled receptors as targets for transformative neuropsychiatric therapeutics.American journal of physiology. Cell physiology · 2023Review
- Review
- Psychedelic-Induced Serotonin 2A Receptor Downregulation Does Not Predict Swim Stress Coping in Mice.International journal of molecular sciences · 2022Article
- The promises and perils of psychedelic pharmacology for psychiatry.Nature reviews. Drug discovery · 2022Review
- Combined Antagonism of 5-HTPharmaceuticals (Basel, Switzerland) · 2022Article
- Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity.Biochemistry · 2022Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 4 countries.
Funding
Abstract
Here, we report that postsynaptic density protein of 95 kDa (PSD-95), a postsynaptic density scaffolding protein, classically conceptualized as being essential for the regulation of ionotropic glutamatergic signaling at the postsynaptic membrane, plays an unanticipated and essential role in mediating the actions of hallucinogens and atypical antipsychotic drugs at 5-HT(2A) and 5-HT(2C) serotonergic G-protein-coupled receptors. We show that PSD-95 is crucial for normal 5-HT(2A) and 5-HT(2C) expression in vivo and that PSD-95 maintains normal receptor expression by promoting apical dendritic targeting and stabilizing receptor turnover in vivo. Significantly, 5-HT(2A)- and 5-HT(2C)-mediated downstream signaling is impaired in PSD-95(null) mice, and the 5-HT(2A)-mediated head-twitch response is abnormal. Furthermore, the ability of 5-HT(2A) inverse agonists to normalize behavioral changes induced by glutamate receptor antagonists is abolished in the absence of PSD-95 in vivo. These results demonstrate that PSD-95, in addition to the well known role it plays in scaffolding macromolecular glutamatergic signaling complexes, profoundly modulates metabotropic 5-HT(2A) and 5-HT(2C) receptor function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.